Re:Third member of U.S. FDA advisory panel resigns over Alzh...
by thesausageking on Saturday June 12, 2021 @12:31PM
(#27485536)
That's not how that works. If Biogen tried to sell unlabelled bottles of aducanumab, the FDA would come after them in a heartbeat.
Picture the judge in the court case: "So, you developed this new molecule that never existed before, spent years testing it to treat alzheimer's, there's been hundreds of news stories about it, there is no other reason a consumer would buy it, and it costs $50k, but you expect the court to believe you didn't think it was being sold as a treatment?"
Biogen won't sell it, but that has little to do with the legality of selling it and everything to do with the fact that they want insurance money and to market this.